Physicians' Education Resource
VerifiedJournal
Physicians' Education Resource®, LLC (PER®) is dedicated to advancing cancer care through professional education.
Accredited by the Accreditation Council for Continuing Medical Education (ACCME) and approved as a nursing continuing education provider by the California Board of Registered Nursing (CBRN), PER® is the educational resource of choice for live and online activities focusing on oncology and hematology. Based on identified needs and practice gaps, PER® provides high-quality, evidence based activities featuring leading national and international faculty with a focus on practice changing advances and standards of care in treatment and disease management. Activities may also include topics on emerging strategies currently under investigation, supportive care, diagnosis and staging, prevention, screening and early detection, and practice management. Source
Actions
Media Outlet details
| Scope | National |
|---|---|
| Language | English |
| Country | United States of America |
Similarweb UVM
|
Request pricing |
Comscore UVM
|
Request pricing |
| Accepts contributed content | Yes |
Recent Articles
Search ArticlesShow Me the Data: Immunotherapy Across the Hepatobiliary Cancer Continuum—From Embolization-Eligible HCC to Advanced Biliary Tract Cancers
OverviewProgram ChairFacultyAccreditation/Credit Designation Overview: The management of hepatobiliary cancers (HBCs), including hepatocellular carcinoma (HCC) and biliary tract cancers (BTC), is rapidly evolving as immunotherapy-based strategies expand across multiple disease settings.
18th Annual International Symposium on Ovarian Cancer and Other Gynecologic Malignancies™
OverviewAgendaAccreditation/Credit DesignationOpportunitiesRefund Policy The management of ovarian, endometrial, and cervical cancers is rapidly evolving with the emergence of biomarker-driven therapies, novel drug classes, and multidisciplinary care strategies. Clinicians must navigate complex treatment decisions, apply trial findings to real-world settings, and individualize care for diverse patient populations—highlighting ongoing challenges in this field.
Show Me Your Care Plan™: Navigating Biomarkers to Guide and Support NSCLC Care
Program InfoFacultyDisclosures/Disclaimers Activity Overview This online, on-demand virtual symposium brings together renowned experts in non–small cell lung cancer (NSCLC). In this educational program, these experts use a combination of didactic presentations and case-based discussions to examine biomarker testing, then move through targeted therapy updates across key biomarker-driven subtypes, with a focus on adverse event recognition and management strategies relevant to the practicing nurse.
21st Annual New York Lung Cancers Symposium®
The program co-chairs of the 21st Annual New York Lung Cancers Symposium® are pleased to introduce the first Rising Stars, Fellow to Expert at the 2026 meeting to foster the career development of new physicians. Fellows areinvited to submit abstracts to this year's conference, to be held November 14, 2026, at the New York Hilton Midtown in New York, NY. All accepted submissions will have the opportunity to participate in a poster reception.
Medical Crossfire®: ADCs and Bispecifics in Lung Cancer – Hype, Hope, or a New Standard of Care?
OverviewAgendaProgram ChairSpeakersAccreditation/Credit Designation Overview: ADCs and bispecific antibodies are rapidly changing the treatment landscape in thoracic oncology. In NSCLC, several ADCs and bispecific antibodies are already reshaping established treatment paradigms. In SCLC, novel bispecific T-cell engagers and ADCs are driving meaningful advances in a historically limited therapeutic landscape.
Project ECHO®: Applying PD-L1 Testing in mTNBC: Making Sense of Biomarker-Driven Frontline Care
Program InfoFacultyDisclosures/Disclaimers Activity Overview This online, on-demand virtual symposium brings together renowned experts in metastatic triple-negative breast cancer (TNBC). In this educational program, these experts discuss PD-L1 testing and CPS scoring in metastatic TNBC, including assay selection, interpretation of borderline and discordant results, and access and disparities in biomarker-driven care.
Find your next CME activity.
AI-Powered Search·Beta Ask in plain English. Our AI reads the entire PER catalog and surfaces the courses worth your time — no keyword guessing, no endless filters. Three steps to your next CME activity. This is a discovery assistant — not a clinical Q&A tool. It always points you to the course worth taking, never replaces it. 01 Describe what you want to learn the same way you'd ask a colleague. No keyword jargon or filter combinations required.
DSUI Urology on the Beach 2027
Join Drs. Dipen J. Parekh and Mark L. Gonzalgo along with the Desai Sethi Urology Institute on the shores of Miami Beach for the 5th Annual Urology on the Beach, a premier educational experience bringing together leading voices in urology for three days of learning, collaboration, and connection. As part of UHealth, University of Miami Health System, the Desai Sethi Urology Institute hosts a meeting experience that is increasingly rare in today's conference landscape.
Oncology Town Hall: From Evidence to Action—Applying KRAS-Targeted Advances in Solid Tumors
Assistant Attending Physician Section Head of Oral Therapeutics, Early Drug Development Service Memorial Sloan Kettering Cancer Center New York, NY Disclosures: Advisor, Consultant, Fee for Service Recipient: Axiom Healthcare, Blueprint Bio, Boehringer Ingelheim, Day One Biopharmaceuticals, Endeavor Biomedicines, Guardant, Mersana, Merus, Partner Therapeutics, PMV Pharma, Redona Therapeutics, Relay Therapeutics, Repare Therapeutics, Revolution Medicines, Schrodinger, TransCode Therapeutics,...
CE - Physicians' Education Resource
You need to enable javascript to view this website.